- Trials with a EudraCT protocol (26)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
26 result(s) found for: eosinophilic esophagitis.
Displaying page 1 of 2.
EudraCT Number: 2017-003737-29 | Sponsor Protocol Number: BUU-5/EEA | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomized, placebo-controlled, Phase II/III trial on the efficacy and tolerability of treatment with budesonide oral suspension vs. placebo in children and adolescents with eosinophi... | |||||||||||||
Medical condition: Active eosinophilic esophagitis and maintenance of remission in eosinophilic esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) PT (Completed) NL (Completed) GR (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002465-30 | Sponsor Protocol Number: EE-01bude2014 | Start Date*: Information not available in EudraCT |
Sponsor Name:Dip. Pediatria UOC Gastroenterologia ed Epatologia Pediatrica | ||
Full Title: Spontaneous study on the efficacy and safety of an oral viscous suspension of budesonide administered to children affected by eosinophilic esophagitis. | ||
Medical condition: Eosinophilic Esophagitis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001314-37 | Sponsor Protocol Number: BUL-8/EEA | Start Date*: 2021-04-26 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, double-dummy, randomized, parallel-group, non-inferiority phase III trial on the efficacy and tolerability of 2 mg once daily vs. 1 mg twice daily budesonide orodispersible tablets fo... | |||||||||||||
Medical condition: eosinophilic esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) PT (Ongoing) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001484-12 | Sponsor Protocol Number: BUL-1/EEA | Start Date*: 2015-09-22 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomized, placebo-controlled, phase III trial on the efficacy and tolerability of a 6-week treatment with budesonide effervescent tablets vs. placebo for induction of clinico-pathol... | |||||||||||||
Medical condition: Active eosinophilic esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003226-23 | Sponsor Protocol Number: APD334-206 | Start Date*: 2021-02-02 | |||||||||||
Sponsor Name:Arena Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis | |||||||||||||
Medical condition: Eosinophilic Esophagitis (EoE) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001786-12 | Sponsor Protocol Number: CDX0159-08 | Start Date*: 2023-03-31 | |||||||||||
Sponsor Name:Celldex Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The "EvolvE" Study) | |||||||||||||
Medical condition: Eosinophilic esophagitis (EoE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) IT (Ongoing) PL (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003516-39 | Sponsor Protocol Number: BUL-3/EER | Start Date*: 2021-04-28 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomized phase III trial in adult and adolescent patients with eosinophilic esophagitis to prove superiority compared to placebo of an episodic and/or a continuous 48-week treatment... | |||||||||||||
Medical condition: Maintenance of remission in eosinophilic esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016692-29 | Sponsor Protocol Number: BUU-2/EEA | Start Date*: 2012-02-20 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, double-dummy, randomized, placebo-controlled, phase IIa study on the efficacy and tolerability of a 14-day treatment with budesonide effervescent tablets vs. viscous budesonide suspen... | |||||||||||||
Medical condition: Active eosinophilic esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001485-99 | Sponsor Protocol Number: BUL-2/EER | Start Date*: 2015-12-08 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for mai... | |||||||||||||
Medical condition: Maintenance of remission in eosinophilic esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) DK (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004335-24 | Sponsor Protocol Number: CC-93538-EE-002 | Start Date*: 2022-01-14 | |||||||||||
Sponsor Name:Celgene International II Sàrl | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS | |||||||||||||
Medical condition: EOSINOPHILIC ESOPHAGITIS | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) IT (Ongoing) AT (Ongoing) PT (Trial now transitioned) PL (Ongoing) BE (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005842-39 | Sponsor Protocol Number: 226361 | Start Date*: 2013-12-20 |
Sponsor Name:NU-sjukvården, Norra Älvsborgs Länssjukhus | ||
Full Title: Treatment of eosinophilic esophagitis with mometason furoat aerosol: a randomised, placebo-controled phase II study for evaluation of treatment effect on group level including symtom questionnaires | ||
Medical condition: Eosinphilic Esophagitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001294-31 | Sponsor Protocol Number: D5244C00001 | Start Date*: 2022-12-06 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) | |||||||||||||
Medical condition: Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eo... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) SE (Ongoing) SK (Ongoing) ES (Ongoing) CZ (Ongoing) DK (Ongoing) GR (Ongoing) FI (Ongoing) DE (Ongoing) BE (Ongoing) NL (Ongoing) IT (Ongoing) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004336-16 | Sponsor Protocol Number: CC-93538-EE-001 | Start Date*: 2021-09-29 | |||||||||||
Sponsor Name:Celgene International II Sàrl | |||||||||||||
Full Title: A Phase 3, Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subject... | |||||||||||||
Medical condition: EOSINOPHILIC ESOPHAGITIS | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) AT (Ongoing) PT (Ongoing) BE (Ongoing) PL (Ongoing) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003078-24 | Sponsor Protocol Number: R668-EE-1877 | Start Date*: 2020-09-01 | ||||||||||||||||
Sponsor Name:Regeneron Pharmaceuticals | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis | ||||||||||||||||||
Medical condition: Eosinophilic Esophagitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002691-14 | Sponsor Protocol Number: RC2019.1.6_ROSSI | Start Date*: 2019-10-30 | |||||||||||
Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA | |||||||||||||
Full Title: VISCOUS BUDESONIDE IN PATIENTS AFFECTED BY EOSINOPHILIC ESOPHAGITIS, OPERATED FOR ESOPHAGEAL ATRESIA | |||||||||||||
Medical condition: Eosinophilicesophagitis (EoE) in Esophageal atresia (EA). | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004391-19 | Sponsor Protocol Number: AK002-14 | Start Date*: 2020-07-30 | |||||||||||
Sponsor Name:Allakos Inc. | |||||||||||||
Full Title: A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis | |||||||||||||
Medical condition: Active Eosinophilic Esophagitis (EoE) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002871-32 | Sponsor Protocol Number: D3255C00001 | Start Date*: 2020-02-05 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA) | |||||||||||||
Medical condition: Eosinophilic Esophagitis (EoE) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000844-25 | Sponsor Protocol Number: R668-EE-1774 | Start Date*: 2019-10-21 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE) | |||||||||||||
Medical condition: Eosinophilic Esophagitis (EoE) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Ongoing) SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PT (Completed) BE (Completed) IT (Completed) ES (Restarted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000082-16 | Sponsor Protocol Number: ACESO | Start Date*: 2021-01-21 | |||||||||||
Sponsor Name:EsoCap AG | |||||||||||||
Full Title: A randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis | |||||||||||||
Medical condition: Active eosinophilic esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001521-27 | Sponsor Protocol Number: SP-1011-003 | Start Date*: 2020-08-03 | |||||||||||
Sponsor Name:Adare Pharmaceuticals US, LP | |||||||||||||
Full Title: Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects w... | |||||||||||||
Medical condition: Eosinophilic Esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.